Get all premium features to the best stock analysis tool

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China

Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China. Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta® while Innovent Biologics holds sole commercialization rights for Vanflyta® in China, leading market promotion.